Irma Convertino

659 total citations
32 papers, 395 citations indexed

About

Irma Convertino is a scholar working on Infectious Diseases, Toxicology and Rheumatology. According to data from OpenAlex, Irma Convertino has authored 32 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Toxicology and 7 papers in Rheumatology. Recurrent topics in Irma Convertino's work include Biosimilars and Bioanalytical Methods (7 papers), Pharmacovigilance and Adverse Drug Reactions (7 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Irma Convertino is often cited by papers focused on Biosimilars and Bioanalytical Methods (7 papers), Pharmacovigilance and Adverse Drug Reactions (7 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Irma Convertino collaborates with scholars based in Italy, United States and Australia. Irma Convertino's co-authors include Marco Tuccori, Corrado Blandizzi, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi, Fabrizio Maggi, Stefania Mantarro, Luca Antonioli and Matteo Fornai and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Critical Care.

In The Last Decade

Irma Convertino

27 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Irma Convertino Italy 11 182 49 48 45 37 32 395
Ana Hidalgo‐Simon Netherlands 9 35 0.2× 24 0.5× 54 1.1× 69 1.5× 22 0.6× 15 355
Ali Saffaei Iran 12 388 2.1× 49 1.0× 31 0.6× 9 0.2× 41 1.1× 57 664
Sara Ferraro Italy 10 185 1.0× 53 1.1× 41 0.9× 31 0.7× 13 0.4× 29 358
Louise M. Andrews Netherlands 14 118 0.6× 37 0.8× 20 0.4× 9 0.2× 154 4.2× 24 654
Hélène Théophile France 15 42 0.2× 28 0.6× 43 0.9× 228 5.1× 71 1.9× 28 602
Anders Helldén Sweden 11 62 0.3× 16 0.3× 9 0.2× 37 0.8× 12 0.3× 23 417
Gowtham Rao United States 11 124 0.7× 29 0.6× 12 0.3× 23 0.5× 65 1.8× 25 455
Wenjuan Wang China 14 162 0.9× 72 1.5× 22 0.5× 3 0.1× 28 0.8× 47 656

Countries citing papers authored by Irma Convertino

Since Specialization
Citations

This map shows the geographic impact of Irma Convertino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irma Convertino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irma Convertino more than expected).

Fields of papers citing papers by Irma Convertino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irma Convertino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irma Convertino. The network helps show where Irma Convertino may publish in the future.

Co-authorship network of co-authors of Irma Convertino

This figure shows the co-authorship network connecting the top 25 collaborators of Irma Convertino. A scholar is included among the top collaborators of Irma Convertino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irma Convertino. Irma Convertino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Marín, Gustavo H., Lisa Pont, Irma Convertino, et al.. (2024). A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy. Therapeutic Innovation & Regulatory Science. 58(3). 549–556. 1 indexed citations
3.
Convertino, Irma, Massimiliano Cazzato, Rosa Gini, et al.. (2023). Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy. Frontiers in Pharmacology. 14. 1244486–1244486.
4.
Convertino, Irma, Valentina Lorenzoni, Rosa Gini, et al.. (2023). Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals. 16(3). 465–465. 1 indexed citations
5.
Valdiserra, Giulia, Nadia Mores, Laura Sottosanti, et al.. (2023). Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation. SHILAP Revista de lepidopterología. 3. 1194683–1194683. 2 indexed citations
6.
Ferraro, Sara, Emiliano Cappello, Claudia Bartolini, et al.. (2023). Potential missed diagnoses of Crohn’s disease in tertiary care: impact on drug utilization and healthcare facilities use. European Journal of Gastroenterology & Hepatology. 35(11). 1263–1269.
7.
Tuccori, Marco, Irma Convertino, Sara Ferraro, et al.. (2022). Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert Opinion on Drug Discovery. 17(6). 531–546. 4 indexed citations
8.
Convertino, Irma, Rosa Gini, Massimiliano Cazzato, et al.. (2021). Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. Journal of Clinical Medicine. 10(24). 5743–5743. 3 indexed citations
9.
Tuccori, Marco, Rosa Gini, Giuseppe Turchetti, et al.. (2021). Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study. CINECA IRIS Institutial research information system (University of Pisa). 1 indexed citations
10.
Convertino, Irma, Marco Tuccori, Sara Ferraro, et al.. (2020). Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 24(1). 331–331. 42 indexed citations
11.
Tuccori, Marco, Irma Convertino, Sara Ferraro, et al.. (2020). The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Safety. 43(8). 699–709. 55 indexed citations
12.
Ferraro, Sara, Marco Tuccori, Irma Convertino, et al.. (2020). Olfactory and gustatory impairments in COVID‐19 patients: Role in early diagnosis and interferences by concomitant drugs. British Journal of Clinical Pharmacology. 87(5). 2186–2188. 3 indexed citations
13.
Ferraro, Sara, Luca Leonardi, Irma Convertino, Corrado Blandizzi, & Marco Tuccori. (2019). Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. Frontiers in Pharmacology. 10. 247–247. 11 indexed citations
14.
Ferraro, Sara, Luca Leonardi, Corrado Blandizzi, Irma Convertino, & Marco Tuccori. (2019). Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports. Drug Safety. 42(10). 1207–1208. 2 indexed citations
15.
Convertino, Irma, Stefano Salvadori, Sara Ferraro, et al.. (2018). Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis. Drug Safety. 42(3). 427–444. 7 indexed citations
16.
Tuccori, Marco, et al.. (2017). Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. Expert Opinion on Drug Safety. 16(10). 1133–1148. 4 indexed citations
17.
Convertino, Irma, Stefano Salvadori, Tamara Knežević, et al.. (2017). Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. Drug Safety. 40(10). 895–909. 17 indexed citations
18.
Convertino, Irma, Stefania Mantarro, Luca Antonioli, et al.. (2016). Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. Drug Safety. 39(10). 903–924. 18 indexed citations
19.
Mantarro, Stefania, Marco Tuccori, Elisa Ruggiero, et al.. (2015). Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Safety. 38(10). 869–888. 13 indexed citations
20.
Mantarro, Stefania, Corrado Blandizzi, Stefania Montagnani, et al.. (2014). Update of Certolizumab Pegol Safety Profile: A Systematic Review and Meta-Analysis. Drug Safety. 37(10). 844–845. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Hidalgo‐Simon Breakdown of academic impact, for papers by Ali Saffaei Breakdown of academic impact, for papers by Sara Ferraro Breakdown of academic impact, for papers by Louise M. Andrews Breakdown of academic impact, for papers by Hélène Théophile Breakdown of academic impact, for papers by Anders Helldén Breakdown of academic impact, for papers by Gowtham Rao Breakdown of academic impact, for papers by Wenjuan Wang
Rankless by CCL
2026